美通社

2024-10-16 13:35

Frost & Sullivan grants the 2024 Global Pluripotent stem cell drug R&D Innovation Award to ZEPHYRM BIOTECHNOLOGIES

SHANGHAI, Oct. 16, 2024 /PRNewswire/ -- The 18th The Growth Innovation Leadership (GIL) Council & the 3rd New Investment Conference in 2024 was held in Shanghai from August 28 to 30, 2024. On the evening of August 28, the prestigious 2024 Global and China Awards for Growth, Innovation, and Leadership and Best Practice Awards were grandly announced at the 2024 GIL Awards Ceremony & VIP Appreciation Dinner.

Based on research and analysis of the global Pluripotent stem cell drug market, as well as studies and evaluations of relevant companies in the industry, Frost & Sullivan has granted EPHYRM BIOTECHNOLOGIES the Global Pluripotent stem cell drug R&D Innovation Award. Mr. Aroop Zutshi, the Global Managing Partner and Executive Board Member of Frost & Sullivan, and Professor Yu Wang, the Chairman of Chinese Foundation for Hepatitis Prevention and Control and the Director General of Chinese Center for Disease Control and Prevention presented this award to Dr. Yi Jia, CMO of ZEPHYRM BIOTECHNOLOGIES.

ZEPHYRM BIOTECHNOLOGIES is a leading Chinese enterprise specializing in the research, development, and production of stem cell drugs

Founded in 2018 with its headquarters in Beijing, ZEPHYRM BIOTECHNOLOGIES is a pioneering biopharmaceutical company in China that focuses on the development and production of pluripotent stem cell drugs. Leveraging the advantages of its pluripotent stem cell seed bank, the company has established a differentiation process and formulation research system for functional cells of different germ layers, thereby constructing a pluripotent stem cell drug platform. Multiple pipelines have progressed to Phase II clinical development.

Accelerating Innovation and Commercialization of Stem Cell Technology for Revolutionary Breakthroughs in Disease Treatment

In June 2019, ZEPHYRM BIOTECHNOLOGIES entered into a strategic cooperation agreement with the Institute of Zoology, Chinese Academy of Sciences, to develop pluripotent stem cell drugs with China's independent intellectual property rights. This endeavor aims to address unmet medical needs that traditional drugs and therapies cannot fulfill, thereby advancing the clinical application and industrial transformation of stem cells. In 2023, ZEPHYRM BIOTECHNOLOGIES received approval from the National Medical Products Administration (NMPA) to conduct Phase II clinical trials for CAStem cell injection in two indications: acute graft-versus-host disease and acute exacerbation of interstitial lung disease. Prior to this, the company had already received NMPA approval for Phase I clinical trials of CAStem cell injection for the treatment of acute respiratory distress syndrome and meniscal injury.

Distinct Product Advantages and Development of Indications to Meet Diverse Clinical Treatment Needs

The stem cell drugs developed by ZEPHYRM BIOTECHNOLOGIES are derived from different functional cells differentiated from human embryonic stem cells. The primary advantages lie in the consistent and stable source of seed cells, ensuring identical biological characteristics across different batches of cell products. The manufacturing process adheres to GMP standards, paving the way for future large-scale industrial production. Based on the unique characteristics of its products, ZEPHYRM BIOTECHNOLOGIES focuses on developing indications for diseases that currently lack effective treatments and clinical applications for sudden emergency medical events/epidemics. Currently, the company is concurrently conducting pharmaceutical research, preclinical trials, and registrational clinical trials for various indications, including acute respiratory distress syndrome and acute exacerbation of interstitial lung disease in the respiratory system, graft-versus-host disease in the immune system, and meniscal injury in the musculoskeletal system.

About Frost & Sullivan's Global Leadership Award

The Frost & Sullivan Global Leadership Award recognizes enterprises' outstanding performance and exceptional achievements in areas such as technology innovation, market potential, customer service, branding, and others. The Frost & Sullivan team nominated a group of competitive and excellent enterprises through methods including in-depth interviews, industry analysis, and secondary research. An independent judging panel, made up of third-party investment and financing experts, financial experts, bankers, and renowned listed company entrepreneurs, conducted rigorous evaluations of the nominated enterprises and decided to grant the 2024 Global Pluripotent stem cell drug R&D Innovation Award to ZEPHYRM BIOTECHNOLOGIES.

source: Frost & Sullivan

【你點睇?】特朗普當局擬關閉美國國家民主基金會,你認為若其關閉是否可促進全球和平穩定?► 立即投票

人氣文章
最近7天
1
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
2
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
3
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
4
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
5
高息定存 | 信銀國際12個月港元定存高達3.5厘
6
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
7
David Webb:因病情惡化,將有序結束個人財經網站
8
港股 | 蕭猷華:恒指短線回調,中線繼續看好
9
iPhone SE 4或於本周內上架官網
10
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
4
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
5
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
6
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
7
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
8
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
9
一本萬利 | 2025年的五個「勿」(有片)
10
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
11
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
14
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
15
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
16
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
17
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
18
習近平應約與特朗普通電話,特:冀盡快與習見面
19
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
20
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
21
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
22
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
23
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
24
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
25
特朗普就職 | 特朗普上台後行動列表
26
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
27
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
28
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
29
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
30
高息定存 | 富邦一周港元定存高達9.88厘,一個月4.88厘
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老